
What smart money is saying about Fortrea
1 fund in our archive has pitched Fortrea — most recently Curreen Capital in June 2025.
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
Get an email when a fund writes about it
Fund coverage · 1 thesis
- Curreen CapitalJune 2025
Despite near-term struggles post-spinoff, Fortrea is a high-potential clinical trials firm poised for a turnaround, backed by growing demand, strong industry positioning, and a capital-light model with high barriers to entry—making its current distressed valuation an appealing contrarian bet.
Read the full thesis
Read every full thesis on Fortrea
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→